MedTrace Logo

Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

NCT01323998 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35032

Last updated 2017-07-06

Study results available
· View outcomes & findings →

Summary

This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)

Conditions

  • Prostatic Hyperplasia

Interventions

DRUG

5ARI

Dutasteride or Finasteride

DRUG

AB

Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01323998 on ClinicalTrials.gov